P
6.64
0.37 (5.90%)
| Penutupan Terdahulu | 6.27 |
| Buka | 6.31 |
| Jumlah Dagangan | 724,098 |
| Purata Dagangan (3B) | 924,677 |
| Modal Pasaran | 562,361,536 |
| Harga / Jualan (P/S) | 2.35 |
| Harga / Buku (P/B) | 1.63 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -104.52% |
| Margin Operasi (TTM) | -55.94% |
| EPS Cair (TTM) | -1.73 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 40.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 27.08% |
| Nisbah Semasa (MRQ) | 4.68 |
| Aliran Tunai Operasi (OCF TTM) | -50.77 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.16 M |
| Pulangan Atas Aset (ROA TTM) | -18.78% |
| Pulangan Atas Ekuiti (ROE TTM) | -57.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | Personalis, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.8
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.75 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.30% |
| % Dimiliki oleh Institusi | 53.15% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Blue Water Life Science Advisors, Lp | 30 Sep 2024 | 1,000,000 |
| State Of Michigan Retirement System | 30 Sep 2024 | 493,798 |
| Wellington Shields Capital Management, Llc | 30 Sep 2024 | 432,181 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 11.00 (HC Wainwright & Co., 65.66%) | Beli |
| Median | 9.13 (37.50%) | |
| Rendah | 7.25 (Needham, 9.19%) | Beli |
| Purata | 9.13 (37.50%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 5.75 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Dec 2024 | 11.00 (65.66%) | Beli | 5.75 |
| Needham | 20 Dec 2024 | 7.25 (9.19%) | Beli | 5.75 |
| 07 Nov 2024 | 7.25 (9.19%) | Beli | 4.32 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Dec 2024 | Pengumuman | Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna |
| 16 Dec 2024 | Pengumuman | Personalis and Tempus Expand Collaboration to Biopharma |
| 20 Nov 2024 | Pengumuman | Personalis to Participate at Upcoming Investor Conferences |
| 06 Nov 2024 | Pengumuman | Personalis Reports Third Quarter 2024 Financial Results |
| 05 Nov 2024 | Pengumuman | Personalis to Present at the Stifel 2024 Healthcare Conference |
| 23 Oct 2024 | Pengumuman | Personalis to Announce Third Quarter 2024 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |